Polish Myeloma Consortium
Clinical trials sponsored by Polish Myeloma Consortium, explained in plain language.
-
Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
Disease control Not yet recruitingThis trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…
Phase: PHASE2 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a dual immunotherapy erase hidden myeloma cells?
Disease control Not yet recruitingThis phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…
Phase: PHASE3 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC